For a decade CRISPR was a headline technology. In December 2023 it became a medicine. Casgevy — co-developed by Vertex and CRISPR Therapeutics — was the first FDA-approved therapy to use CRISPR/Cas9 genome editing, cleared for eligible patients with sickle cell disease and later transfusion-dependent beta thalassemia.
The applied story is not the Nobel Prize. It is the treatment path: a patient’s blood stem cells are collected, edited so red cells produce more fetal hemoglobin, and returned. Vertex has reported real infusions, growing reimbursed access, and hundreds of patients initiating treatment since launch. In 2026 the FDA expanded Casgevy to children as young as two for eligible indications — moving gene editing deeper into pediatric care.
That still does not make CRISPR a casual clinic visit. Authorized treatment centers, cell collection, conditioning, and cost are part of the applied reality. But the category shift is done: gene editing is no longer only a paper. It is a one-time therapy with a label, a supply chain, and patients who have finished the process.
For appliedscience.com, Casgevy is the clearest “science used on people today” card in biotech. The follow-up stories write themselves — access, durability of benefit, and which diseases get the next approved edits.